BioSpace News Archive

Owens & Minor, Inc. announced that the company will participate in the BofA Securities 2020 Leveraged Finance Conference on December 1, 2020.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercore’s 3rd Annual HealthCONx virtual conference at 11:20 a.m. ET on Thursday, December 3, 2020.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore.

Combines Codexis’ R&D and commercialization platform with Casdin Capital’s investment expertiseto investin and support innovative early stage life science and synthetic biologytechnology companies

Awardees DC Medical and deepmedi recognized for pioneering efforts leveraging data and health technologies to advance potentially life-saving ideas aimed at improving patient care during the COVID-19 pandemic and beyond.

Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO, announced the completion of the previously announced offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029.

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a Phase Ib/II clinical study of the company’s novel Bcl-2 inhibitor APG-2575,

CorticoMetrics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for THINQ™, its AI-based software for use by radiologists and neurologists providing quantitative information to augment patient assessment for a number of neurological disorders and conditions. THINQ™ automatically se

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will present on Wednesday, December 2, 2020 at the Evercore ISI 3rd Annual HealthCONx Conference.

Reata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration completed its internal review of the Baseline-Controlled Study results of omaveloxolone for the treatment of patients with Friedreich’s ataxia and concluded that the results do not strengthen the results of Part 2 of the MOXIe study.